Upload Avatar (500 x 500)
Chao Liang
Life Science
Southern University of Science and Technology
Guangdong
Language: Chinese, English
Bone Disease
Joint Disease
Tumor Mechanisms
Translational Medicine
Precision Medicine
Research
Therapy
Diagnosis
Treatment
Medical Science
Areas of Focus
- Bone and joint related diseases and tumor mechanisms, translational medicine, and precision medicine
Work Experience
- 2020-present, Associate Professor, Southern University of Science and Technology
- 2018-2020, Research Assistant Professor, Hong Kong Baptist University
- 2016-2018, Postdoctoral Fellow, Hong Kong Baptist University
Academic Background & Achievements
- 2013-2016 PhD: Hong Kong Baptist University
- 2010-2013 Master of Science: Anhui Medical University - Military Medical Science Academy
- 2006-2010 Bachelor of Science: Shandong First Medical University
Publications
- Gut microbial metabolite targets HDAC3-FOXK1-interferon axis in fibroblast-like synoviocytes to ameliorate rheumatoid arthritis, Chao Liang et al., 2024
- CRISPRa engineered Elite macrophages enable adoptive cell therapy for rheumatoid arthritis, Chao Liang et al., 2024
- Repurposing AS1411 for constructing ANM-PROTACs, Chao Liang et al., 2024
- Bone disease imaging through the near-infrared-II window, Chao Liang et al., 2023
- Targeted protein degradation in cancers: Orthodox PROTACs and beyond, Chao Liang et al., 2023
- Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment, Chao Liang et al., 2022
- Therapeutic Effects of (5R)-5-Hydroxytriptolide on Fibroblast-Like Synoviocytes in Rheumatoid Arthritis via lncRNA WAKMAR2/miR-4478/E2F1/p53 Axis, Chao Liang et al., 2021
- Silencing of miR-138-5p sensitizes bone anabolic action to mechanical stimuli, Chao Liang et al., 2020
- Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy, Chao Liang et al., 2015
- Inhibition of osteoblastic Smurf1 promotes bone formation in mouse models of distinctive age-related osteoporosis, Chao Liang et al., 2018
- HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis, Chao Liang et al., 2019
- Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma, Chao Liang et al., 2017
- A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer, Chao Liang et al., 2017
- A newly identified lncRNA MAR1 acts as a miR-487b sponge to promote skeletal muscle differentiation and regeneration, Chao Liang et al., 2018
- Osteoblastic PLEKHO1 contributes to joint inflammation in rheumatoid arthritis, Chao Liang et al., 2019
- Increased PLEKHO1 within osteoblasts suppresses Smad-dependent BMP signaling to inhibit bone formation during aging, Chao Liang et al., 2017
- Long Noncoding RNA lncMUMA Reverses Established Skeletal Muscle Atrophy following Mechanical Unloading, Chao Liang et al., 2018
- TAK1 inhibition attenuates both inflammation and fibrosis in experimental pneumoconiosis, Chao Liang et al., 2017
- PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs, Chao Liang et al., 2017
- Comparison of the methods for generating single-stranded DNA in SELEX, Chao Liang et al., 2015
- Identification of UHRF1/2 as new N-methylpurine DNA glycosylase-interacting proteins, Chao Liang et al., 2013
Awards
- 2020: Shenzhen Overseas High-level Talent
- 2019: National Outstanding Youth
